Current stock page

Financial Data

FATE Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Sep 4, 2026

FATE

Financial Data
Fate Therapeutics, Inc.
Healthcare· Biotechnology
AIQ Score
BearishAIQ Edge 1/10
Low Priority
Relative Laggard
Score data as of Sep 4, 2026
Last price
$2.48
+$0.06 (+2.48%)
Latest market quote
Momentum43
Value34
Quality23
Risk Resilience34
Sentiment
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 6, 2026.

Income statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Revenue$2.08M$1.3M$1.37M$1.74M$1.91M$1.63M$1.86M$3.07M
Gross Profit$2.08M-$1.62M$1.37M$1.74M$1.91M$1.63M$1.86M$3.07M
Operating Income
Net Income-$30.16M-$31.21M-$32.37M-$32.25M-$34.07M-$37.62M-$52.15M-$47.68M
EPS-$0.25-$0.26-$0.27-$0.27-$0.29-$0.32-$0.44-$0.4
Cash flow statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Operating Cash Flow-$23.43M-$30.82M-$23.31M-$24.37M-$24.59M-$33.81M-$27.8M-$29.42M
Capital Expenditure-$80K-$239K-$1.19M-$2.2M-$1.36M-$1.2M-$98K-$495K
Free Cash Flow-$23.51M-$31.06M-$24.51M-$26.58M-$25.95M-$35.01M-$27.9M-$29.91M
Net Cash Provided By Operating Activities-$23.43M-$30.82M-$23.31M-$24.37M-$24.59M-$33.81M-$27.8M-$29.42M
Balance sheet
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Assets$260.1M$284.92M$318.94M$343.67M$371.63M$398.67M$440.69M$494.97M
Total Debt$75.68M$76.79M$77.85M$79.25M$81.33M$83.33M$85.27M$98.98M
Cash And Cash Equivalents
Total Liabilities$106.67M$105.21M$111.75M$109.61M$110.27M$110.26M$121.97M$132.64M
Total Stockholders Equity$153.44M$179.71M$207.18M$234.07M$261.36M$288.41M$318.73M$362.33M
Key financial metrics
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio-2.7-1.15-0.91-1.16-0.97-0.62-0.93-2.16
P/B ratio2.120.80.560.640.510.320.611.14
P/S ratio156.13110.8885.2686.1269.6157.41104.5134.09
Debt To Equity0.490.430.380.340.310.290.270.27
Free Cash Flow Yield
Financial ratios
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio
P/B ratio2.120.80.560.640.510.320.611.14
P/S ratio156.13110.8885.2686.1269.6157.41104.5134.09
Return On Equity-19.66%-17.37%-15.63%-13.78%-13.04%-13.04%-16.36%-13.16%
Debt To Equity

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
-2.31
multipleSep 4, 2026
Pb
1.91
multipleSep 4, 2026
Revenue Growth Yoy
60.28
percentSep 4, 2026
EPS Growth Yoy
3.85
percentSep 4, 2026
Gross Margin
-343.01
percentSep 4, 2026
Operating Margin
-2,058.08
percentSep 4, 2026
ROE
-65.08
percentSep 4, 2026
ROIC
-57.47
percentSep 4, 2026
Debt To Equity
0.49
ratioSep 4, 2026
FCF Yield
-37.3
percentSep 4, 2026
Technical indicators
Close
2.48
priceSep 4, 2026
Volume
611,433
volumeSep 4, 2026
Rsi14
43.27
indexSep 4, 2026
MACD
-0.04
indexSep 4, 2026
MACD Signal
-0.03
indexSep 4, 2026
MACD Histogram
-0.01
indexSep 4, 2026
Adx14
13.41
indexSep 4, 2026
Sma50
2.63
priceSep 4, 2026
Sma200
1.72
priceSep 4, 2026
Atr14
0.16
priceSep 4, 2026
Historical Volatility
0.56
percentSep 4, 2026
Volume Ma20
1,433,064.95
volumeSep 4, 2026
Risk measures
Resilience Score
34
score_0_100Sep 4, 2026
Beta
2.55
ratioSep 4, 2026
Volatility Annual
96.19
percentSep 4, 2026
Max Drawdown
-41.58
percentSep 4, 2026
Sharpe Ratio
1.4
ratioSep 4, 2026
Var95
-8.65
percentSep 4, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

FATE Financial Data FAQ

What is Fate Therapeutics, Inc.'s revenue?

Fate Therapeutics, Inc.'s revenue is one of the core financial data points for FATE. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Fate Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Fate Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is FATE's EPS?

FATE's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Fate Therapeutics, Inc.'s net income?

Fate Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Fate Therapeutics, Inc. generate?

Free cash flow shows how much cash Fate Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Fate Therapeutics, Inc. have?

Cash and debt help frame FATE's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.